Official Title AMC-111 Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study

Purpose

This clinical trial evaluates the usefulness of using a smartphone-based HIV-specific smoking cessation intervention at the time of lung cancer screening in helping people living with HIV quit smoking. Positively Smoke Free - Mobile may help patients with HIV quit smoking.

 

In this study, you will have lung cancer screening performed via a CT scan. You will also be enrolled into a self-guided smartphone-based HIV-specific smoking cessation intervention called “Positively Smoke Free - Mobile” lasting 42 days. After starting the intervention, you will be evaluated at 3, 6, and 12 months. 

Could this study be right for you?

Must have at least a 20 pack-year history of smoking (a way to measure how much a person has smoked over time, 1 pack-year is a pack per day for a year or 2 packs of cigarettes for half a year, etc.)

Must have not had a CT scan in the past 12 months

HIV positive, and must be receiving antiretroviral therapy and have a CD4 count of at least 200cells/uL within 6 months of enrolling in the study

Able to understand and provide informed consent

Possess a smart phone that can browse the web

Not receiving any other smoking cessation interventions currently or within the prior 30 days

Female volunteers cannot be pregnant, lactating, or breast-feeding

Age Range

45 - 80 years

Official Title LOWFLC Study: Addiction potential of low nicotine filtered little cigars

Purpose

Researchers from The Ohio State University are recruiting adult users of little cigars and cigarillos to help improve understanding of the products’ health impact.

Could this study be right for you?

• Current smoker
• No significant health problems

Age Range

21 - 75 years

Official Title Establishing Reference Values and Clinical Decision Points for Quantitative Videofluoroscopic Measures of Swallowing

Purpose

This study will help create healthy reference values clinicians can use to evaluate adult patients of all ages and is sponsored by the National Institute on Aging.  During this study, we will perform an x-ray swallowing exam and breathing tests with persons who do not have a personal history of swallowing problems or any disorders that could contribute to a swallowing problem.  Study participation will consist of a screening meeting (approximately 15 minutes) via phone call, video chat, or email to verify eligibility, and one in-person visit to our laboratory (approximately 1 hour).

Could this study be right for you?

• If you are biologically female and of child-bearing age (<63), you must not be pregnant or breastfeeding.
• No personal history of surgery or radiation therapy to the head or neck (mouth, jaw, neck, brain, nose, face, thyroid, throat, or voice box) other than having your tonsils, adenoids, or teeth removed.
• No personal history of cancer involving structures of the head, neck, spine, respiratory, or lymphatic system.
• No personal history of stroke or other progressive nerve disease.
• No current diagnosis or personal history of Chronic Obstructive Pulmonary Disease (COPD).
• No known allergies to barium.

Age Range

54 - 89 years

Official Title A prospective randomized unblinded study of ketogenetic versus mixed diet on exercise tolerance in subjects with the metabolic phenotype of heart failure with preserved ejection fraction

Purpose

The purpose of this study is to compare the effects of a well-formulated ketogenic diet with a low-fat diet on exercise tolerance in patients with diabetes or pre-diabetes or obesity; with shortness of breath or heart failure.

Could this study be right for you?

Inclusions:

• Age ≥ 18 years old and ≤ 80 years old & willingness to be randomized to either diet.
• NYHA class I – III for at least 3 months.
• Ejection fraction ≥40% by biplane 2D, or 3D echo, or CMR.
• Echo findings of abnormal or indeterminant diastolic function or RHC data: At rest: mean pulmonary capillary wedge pressure (PCWP) > 15 mmHg. Pulmonary vascular resistance (PVR) < 3 Wood Units.
• Stable medical therapy for at least 3 months as determined by the treating physician (no new cardiac or diabetic medications within 3 months of enrollment or during enrollment and dosage should be stable for 1 month prior to enrollment).
• Dose of oral diuretics changes allowed but must be stable for 1 week prior to randomization.
• Body Mass Index (BMI) ≥ 25 and ≤ 50 or Type 2 Diabetes Mellitus or prediabetes (fasting glucose of 100 - 125 mg/dL or hemoglobin A1C 5.7-6.4%) or metabolic syndrome.
• Ability to participate in exercise treadmill testing.
• Ability to sign written consent.

Exclusions:

• Women who are pregnant, current breast-feeding, or have intention to become pregnant while in the study.
• Known allergy or sensitivity to gadolinium-based contrast agents.
• Implanted pacemaker, cardioverter defibrillator, Cardiac resynchronization therapy, left ventricular assist devices.
• Other metallic implants/aneurysm clips that are contraindicated in MRI.
• Claustrophobia
• History of severe kidney disease of eGFR < 30 ml/kg/1.73m2.

Exclusion Criteria varies, please contact Study Coordinator.

Age Range

18 - 80 years

Official Title Reducing exercise intolerance through inspiratory muscle training in obese breast cancer survivors (IMOCS)

Purpose

The purpose of this study is to better understand why some survivors of breast cancer have difficulty exercising. We also want to learn if breathing exercises can make it easier to tolerate exercise. 

Could this study be right for you?

• Breast Cancer Survivor
• Completed treatment within 6 months–5 years
• Have obesity, defined as body mass index between 30-50 kg/m2
• Can exercise independently

Age Range

18 years and up

Official Title [American Lung Association (ALA)] Lung Health Cohort (LHC) Study

Purpose

The purpose of this study is to examine why some people have better lung function than others as young adults during the period of peak lung health (ages 25 to 35 years old). The long-term goal of this study is to come up with ideas about how to promote the best possible lung function in young adults.

Participation in this study will be 4.5 years.

Could this study be right for you?

Inclusion Criteria:

• Men and women aged 25-35 years old at time of examination
• Able to read and understand English or Spanish
• Have a social security number

Exclusion Criteria:

• Severe asthma or other chronic lung disease
• Diagnosed cardiovascular disease
• History of cancer other than non-melanoma skin cancer
• Currently pregnant

Age Range

25 and up

Official Title A Sham Controlled Prospective Randomized Clinical Trial of the RejuvenAir® System for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease with Chronic Bronchitis (SPRAY-CB)

Purpose

The purpose of this study is to determine the safety and effectiveness of a device called the RejuvenAir® System, developed for patients with chronic bronchitis. The primary objective of this trial is to demonstrate the safety and effectiveness of the RejuvenAir® System for the treatment of adult subjects with a diagnosis of CB defined as COPD with classic 3 months of cough and sputum production for a minimum of 2 years who demonstrate ongoing symptoms of cough and significant mucus production. You will be in the study for approximately 36 months, including the screening period.

Could this study be right for you?

Inclusion Criteria:

1. Males and females 40-80 years of age
2. Must demonstrate daily cough and significant mucus production
3. Have had a diagnosis of chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD) for a minimum of two years. (CB is defined clinically as chronic productive cough for 3 months in each of 2 successive years in a patient in whom other causes of productive cough have been excluded)
4. Smoking history of at least 10 pack years
5. Non-smoking for a minimum of 2 months prior to consent and agrees to continue not smoking for the duration of the study

Exclusion Criteria:

1. Have had an acute pulmonary infection, exacerbation or pneumonia requiring medical treatment (with antibiotics and/or steroids) within 4 weeks prior of initially planned study bronchoscopy
2. Diagnosis of Asthma
3. You have had any type of transplant procedure
4. Use e-cigarettes, vaping or inhaled substances not prescribed by a physician RejuvenAir® System
5. You are pregnant, nursing, or planning to get pregnant during study

* This is not a complete list of either inclusion or exclusion criteria

Age Range

40 and up

Official Title A Multicenter, Randomized, Sham-controlled Study to Evaluate Safety and Efficacy After Treatment with the Nuvaira™ Lung Denervation System in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

Purpose

The purpose of this research study is to evaluate the safety and efficacy of the Nuvaira System, which is made by Nuvaira, Inc., for Targeted Lung Denervation (TLD) Therapy.

The primary purpose of conducting this study is to see if TLD Therapy in addition to optimal medical care (daily breathing medications you have been prescribed by your doctor) is better at reducing a moderate or severe worsening of symptoms (known as an COPD flare-ups or exacerbations) and related hospitalizations than optimal medical care (daily breathing medications you have been prescribed by your doctor) alone.

Could this study be right for you?

Inclusion Criteria:

• Between 40 and 75 years of age
• Non-smoking for a minimum of 2 months prior to consent and agrees to not smoke for the duration of the study
• Diagnosis of COPD with 30% ≤ FEV1 <60% of predicted and FEV1/FVC <70% (post-bronchodilator)
• SpO2 of at least 89% on room air at the time of screening
• Has a documented history of having minimally been taking a regular respiratory maintenance medication for at least 12 months at the time of consent; medications will be reviewed by study team
• If you have participated in a formal pulmonary rehabilitation program recently, program completion should have occurred more than 3 months prior to consent; if in a maintenance program, you will agree to continue your current program through your 12-month follow-up visit;
• Additional criteria will be reviewed by the study team

Involvement in this study will last approximately 62 months.

Age Range

40 and up

Official Title Extracellular vesicles and the development of COPD

Purpose

The study is being done to learn more about how certain smokers develop COPD, chronic obstructive pulmonary disease. By studying microscopic particles (extracellular vesicles) in the blood and lung fluid from smokers we can learn more about this process. This information could lead to better understanding of how smoking damages the lungs and could ultimately help design treatments for people with or at risk for COPD

Could this study be right for you?

• 21 years of age and older
• Current Smoker with at least 10 pack year history
• With or without diagnosis of COPD
• Willing to participate in bronchoscopy procedure
• Not currently diagnosed interstitial lung disease (i.e. sarcoidosis, idiopathic pulmonary fibrosis), lung cancer, primary pulmonary hypertension or have active cardiac disease

Age Range

21 and up

Official Title Biomarkers of Sickle Cell Lung Disease -BOLD

Purpose

This is a study to determine risk factors for developing lung disease in children with sickle cell disease (SCD). Specifically we are researching factors that lead to the development of Acute Chest Syndrome, a pneumonia-like illness that affects many children with SCD.

Could this study be right for you?

• Diagnosis of Sickle Cell Disease (SCD)
• Under the age of 19